PTLF News Alert Petlife Pharmaceuticals Inc. (PTLF) 0.0855 02/15/2015
Post# of 64074
Posted On: 02/15/2015 10:30:57 AM
Petlife Pharmaceuticals Inc. (PTLF) 0.0855 $PTLF
Petlife Pharmaceuticals Announces That Escozine for Human Cancer Treatment Gains Acceptance from Insurance Company in Vietnam
ACCESSWIRE - Thu Dec 18, 7:30AM CST
BEVERLY HILLS, CA / ACCESSWIRE / December 18, 2014 / PetLife Pharmaceuticals, Inc. (OTCQB: PTLF), a developer of new generation high potency veterinary cancer medications and nutraceuticals for pets, today announced that its affiliate company, Medolife Corp., has negotiated an agreement with a new distributor in Vietnam that has an agreement with a health insurance company to cover the cost of patients using the company's Escozine cancer treatment product as part of their cancer therapy.
PetLife Announces Positive Developments in Special Letter to Shareholders
ACCESSWIRE - Thu Dec 11, 7:31AM CST
Beverly Hills, CA / ACCESSWIRE / December 11, 2014 / PetLife Pharmaceuticals, Inc. (OTCQB: PTLF), a developer of new generation of high potency veterinary cancer medications and nutraceuticals for pets, today issued the following Special Letter to Shareholders:
Miami Vets Lead Alternative Pet Cancer Treatment with Escozine for Pets(TM)
ACCESSWIRE - Mon Nov 10, 8:29AM CST
Beverly Hills, CA / ACCESSWIRE / November 10, 2014 / PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) today reported it is seeing Miami-area veterinarians leading the growing trend toward studying and using more cutting-edge treatment of pets to include increasing use of the Company's Escozine for Pets nutraceutical product to treat pets with cancer.
PetLife Reports Positive Veterinary Clinical Pet Data on Escozine for Pets; Cancer-Diagnosed Pets' Quality, and Longevity, of Life Improved and Extended
ACCESSWIRE - Mon Nov 03, 7:32AM CST
Beverly Hills, CA / ACCESSWIRE / November 3, 2014 / PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) today announced it has received positive, preliminary clinical research data from an ongoing study of ten dogs or cats -- diagnosed with cancer - that are being treated with Escozine for Pets(TM). The Study is conducted by Raul Jimenez, DVM, of the prestigious Biscayne Veterinary Center in Miami.
PetLife to Start New Pre-Clinical Study on Escozine for Pets; Results Expected in December
Marketwired - Mon Oct 27, 7:31AM CDT
PetLife Pharmaceuticals, Inc. (OTCQB: PTLF), a registered US Veterinary Pharmaceutical company, today announced it has signed an agreement with AllCells to start a pre-clinical study on its major product Escozine for Pets(TM) with the most common canine cancer tumor cell lines (lymphoma and osteosarcoma). Results are expected in December, after which the Company will announce the conclusions as well as post the Study's final report on its website.
PetLife Receives Initial Equity Funding Commitment for $2.5M to $5M
Marketwire - Mon Sep 22, 7:31AM CDT
PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) today announced it has received a financing offer from an international investment fund for a $2.5 million to $5 million initial, common stock financing.
PetLife Publishes Two White Papers on History and Production of Escozine for Pets(TM)
Marketwire - Wed Sep 17, 11:26AM CDT
PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) today announced it has published two white papers that explain the science underlying Escozine for Pets(TM). The first of which is History of Escozine For Pets, and the second is Stages of Production of Escozine For Pets which contains a highly detailed and scientifically technical analysis of the production and polarization process from start to finish.
Petlife Pharmaceuticals Announces That Escozine for Human Cancer Treatment Gains Acceptance from Insurance Company in Vietnam
ACCESSWIRE - Thu Dec 18, 7:30AM CST
BEVERLY HILLS, CA / ACCESSWIRE / December 18, 2014 / PetLife Pharmaceuticals, Inc. (OTCQB: PTLF), a developer of new generation high potency veterinary cancer medications and nutraceuticals for pets, today announced that its affiliate company, Medolife Corp., has negotiated an agreement with a new distributor in Vietnam that has an agreement with a health insurance company to cover the cost of patients using the company's Escozine cancer treatment product as part of their cancer therapy.
PetLife Announces Positive Developments in Special Letter to Shareholders
ACCESSWIRE - Thu Dec 11, 7:31AM CST
Beverly Hills, CA / ACCESSWIRE / December 11, 2014 / PetLife Pharmaceuticals, Inc. (OTCQB: PTLF), a developer of new generation of high potency veterinary cancer medications and nutraceuticals for pets, today issued the following Special Letter to Shareholders:
Miami Vets Lead Alternative Pet Cancer Treatment with Escozine for Pets(TM)
ACCESSWIRE - Mon Nov 10, 8:29AM CST
Beverly Hills, CA / ACCESSWIRE / November 10, 2014 / PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) today reported it is seeing Miami-area veterinarians leading the growing trend toward studying and using more cutting-edge treatment of pets to include increasing use of the Company's Escozine for Pets nutraceutical product to treat pets with cancer.
PetLife Reports Positive Veterinary Clinical Pet Data on Escozine for Pets; Cancer-Diagnosed Pets' Quality, and Longevity, of Life Improved and Extended
ACCESSWIRE - Mon Nov 03, 7:32AM CST
Beverly Hills, CA / ACCESSWIRE / November 3, 2014 / PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) today announced it has received positive, preliminary clinical research data from an ongoing study of ten dogs or cats -- diagnosed with cancer - that are being treated with Escozine for Pets(TM). The Study is conducted by Raul Jimenez, DVM, of the prestigious Biscayne Veterinary Center in Miami.
PetLife to Start New Pre-Clinical Study on Escozine for Pets; Results Expected in December
Marketwired - Mon Oct 27, 7:31AM CDT
PetLife Pharmaceuticals, Inc. (OTCQB: PTLF), a registered US Veterinary Pharmaceutical company, today announced it has signed an agreement with AllCells to start a pre-clinical study on its major product Escozine for Pets(TM) with the most common canine cancer tumor cell lines (lymphoma and osteosarcoma). Results are expected in December, after which the Company will announce the conclusions as well as post the Study's final report on its website.
PetLife Receives Initial Equity Funding Commitment for $2.5M to $5M
Marketwire - Mon Sep 22, 7:31AM CDT
PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) today announced it has received a financing offer from an international investment fund for a $2.5 million to $5 million initial, common stock financing.
PetLife Publishes Two White Papers on History and Production of Escozine for Pets(TM)
Marketwire - Wed Sep 17, 11:26AM CDT
PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) today announced it has published two white papers that explain the science underlying Escozine for Pets(TM). The first of which is History of Escozine For Pets, and the second is Stages of Production of Escozine For Pets which contains a highly detailed and scientifically technical analysis of the production and polarization process from start to finish.
(0)
(0)Scroll down for more posts ▼